Givosiran
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Intermittent Porphyria
Conditions
Acute Intermittent Porphyria
Trial Timeline
Oct 1, 2016 → Nov 5, 2021
NCT ID
NCT02949830About Givosiran
Givosiran is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Acute Intermittent Porphyria. The current trial status is completed. This product is registered under clinical trial identifier NCT02949830. Target conditions include Acute Intermittent Porphyria.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04056481 | Pre-clinical | Completed |
| NCT02949830 | Phase 1/2 | Completed |
Competing Products
20 competing products in Acute Intermittent Porphyria